New cancer clinical trial: Real World Study on Erlotinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer

Published on: August 27, 2018 at 12:00PM
Condition:   Efficacy and Safety of Erlotinib Combined With Bevacizumab in EGFR Mutation Positive Advanced Non-squamous Non-small Cell Lung Cancer
Intervention:   Drug: erlotinib combined with Bevacizumab
Sponsor:   Hunan Province Tumor Hospital
Recruiting
https://ift.tt/2NqbcDH